Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

Nonalcoholic steatohepatitis (NASH) is a sub-classification of nonalcoholic fatty liver disease (NAFLD) characterized by increased risk of progressive liver fibrosis. Cenicriviroc (CVC) is a novel, orally administered, potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with NASH.

Source: Contemporary Clinical Trials - December 23, 2019 Category: Radiology Authors: Quentin M. Anstee, Brent A. Neuschwander-Tetri, Vincent Wai-Sun Wong, Manal F. Abdelmalek, Zobair M. Younossi, Jiacheng Yuan, Maria Lucia Pecoraro, Star Seyedkazemi, Laurent Fischer, Pierre Bedossa, Zachary Goodman, Naim Alkhouri, Frank Tacke, Arun Sanyal Source Type: research